PG-110 / ProGen - LARVOL DELTA

PG-110, a trispecific actrii/myostatin/gip antibody, improves the quality of semaglutide-induced weight loss beyond body composition compared with bimagrumab (EASD 2026) - "PG-110 enhanced semaglutide-induced fat-selective weight loss while preserving lean mass and improving muscle function, muscle quality, glycemic control, and liver health. Compared with bimagrumab, PG-110 demonstrated integrated benefits beyond body composition, supporting simultaneous targeting of ActRII, myostatin, and GIP pathways as a promising strategy for improving the quality of GLP-1-induced weight loss."

Late-breaking abstract • Trispecific • Metabolic Disorders • Obesity • ACVR2A